Zheng Xiao1, Chengqiong Wang2, Rui Zhou3, Shanshan Hu4, Nian Yi3, Jihong Feng5, Minghua Zhou6, Shiyu Liu6, Ling Chen2, Jie Ding7, Qihai Gong8, Fushan Tang8, Xiaofei Li9. 1. Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China; Department of Respiratory Medicine (Center for Evidence-Based and Translational Medicine of major infectious diseases), Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China. Electronic address: zy426f@163.com. 2. Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China; Department of Respiratory Medicine (Center for Evidence-Based and Translational Medicine of major infectious diseases), Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China. 3. Grade 2013 Students, Department of Public Health, Zunyi Medical College, Zunyi 563003, Guizhou, China. 4. GCP Center, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China. 5. Department of Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China. Electronic address: jh_f@163.com. 6. Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China. 7. Outpatient Department of Psychological Counseling Clinic, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China. 8. School of Pharmacy, Zunyi Medical College, Zunyi 563003, Guizhou, China. 9. Guizhou Provincial College-based Key Lab for Tumor Prevention and Treatment with Distinctive Medicines, Zunyi Medical College, Zunyi 563003, Guizhou, China.
Abstract
OBJECTIVES: Aidi injection can significantly improve clinical response and reduce radiochemotherapy related toxicity. Can Aidi injection improve the survival in non-small-cell lung cancer (NSCLC)? Therefore, to further reveal it, we systematically evaluated all related studies. METHODS: We collected all studies about Aidi injection for NSCLC in Medline, Embase, Web of Science(ISI), China National Knowledge Infrastructure Database(CNKI), Chinese Scientific Journals Full-Text Database(VIP), Wanfang, China Biological Medicine Database (CBM), Cochrane Central Register of Controlled Trials (CENTRAL), Chinese clinical trial registry (Chi-CTR) and WHO International Clinical Trials Registry Platform (WHO-ICTRP), and US-clinical trials (established to June 2016). We evaluated their quality according to the Cochrane evaluation handbook of randomized controlled trials (RCTs) (5.1.0), extracted data following the PICO principles, and synthesized the data by meta-analysis. RESULTS: We included 25 RCTs involving 2662 patients with NSCLC which most studies had unclear risk of bias. The merged risk ratios (RR) values and their 95% CI of meta-analysis for objective response rate (ORR) and disease control rate (DCR) were as following: 1.19(1.09-1.29) and 1.07(1.03-1.11). The merged RR values and their 95% CI of meta-analysis for the 1-, 2- and 3-year overall survival (OS) rate were as following: 1.23(1.14-1.33), 1.46(1.22-1.74) and 1.67(1.04-2.69). All differences were statistically significant. Subgroup analysis showed that Aidi injection plus different therapies had different effects on 1-, 2- and 3-year OS rate. Sensitivity analysis showed that the RR of ORR, DCR, 1- and 2- year OS rate had good stability, and 3-year OS rate had poor stability. CONCLUSIONS: Available evidences indicate that Aidi injection can significantly improve the clinical response and OS rates in patients with NSCLC and especially, the 1- and 2-year OS rate. But, Aidi injection plus different therapies had different effects on overall survival. It is still unclear whether Aidi injection can improve the PFS and HR.
OBJECTIVES:Aidi injection can significantly improve clinical response and reduce radiochemotherapy related toxicity. Can Aidi injection improve the survival in non-small-cell lung cancer (NSCLC)? Therefore, to further reveal it, we systematically evaluated all related studies. METHODS: We collected all studies about Aidi injection for NSCLC in Medline, Embase, Web of Science(ISI), China National Knowledge Infrastructure Database(CNKI), Chinese Scientific Journals Full-Text Database(VIP), Wanfang, China Biological Medicine Database (CBM), Cochrane Central Register of Controlled Trials (CENTRAL), Chinese clinical trial registry (Chi-CTR) and WHO International Clinical Trials Registry Platform (WHO-ICTRP), and US-clinical trials (established to June 2016). We evaluated their quality according to the Cochrane evaluation handbook of randomized controlled trials (RCTs) (5.1.0), extracted data following the PICO principles, and synthesized the data by meta-analysis. RESULTS: We included 25 RCTs involving 2662 patients with NSCLC which most studies had unclear risk of bias. The merged risk ratios (RR) values and their 95% CI of meta-analysis for objective response rate (ORR) and disease control rate (DCR) were as following: 1.19(1.09-1.29) and 1.07(1.03-1.11). The merged RR values and their 95% CI of meta-analysis for the 1-, 2- and 3-year overall survival (OS) rate were as following: 1.23(1.14-1.33), 1.46(1.22-1.74) and 1.67(1.04-2.69). All differences were statistically significant. Subgroup analysis showed that Aidi injection plus different therapies had different effects on 1-, 2- and 3-year OS rate. Sensitivity analysis showed that the RR of ORR, DCR, 1- and 2- year OS rate had good stability, and 3-year OS rate had poor stability. CONCLUSIONS: Available evidences indicate that Aidi injection can significantly improve the clinical response and OS rates in patients with NSCLC and especially, the 1- and 2-year OS rate. But, Aidi injection plus different therapies had different effects on overall survival. It is still unclear whether Aidi injection can improve the PFS and HR.